Why Is Apellis Pharmaceuticals, Inc. (APLS) Down 9.8% Since Last Earnings Report?Zacks Investment Research • 09/07/22
Apellis Announces 24-Month Results Showing Increased Effects Over Time with Pegcetacoplan in Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA)GlobeNewsWire • 08/24/22
Apellis Pharmaceuticals, Inc. (APLS) CEO Cedric Francois on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/09/22
Apellis Pharmaceuticals, Inc. (APLS) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/08/22
Apellis Pharmaceuticals to Host Conference Call on Aug 8, 2022 to Discuss Second Quarter 2022 Financial ResultsGlobeNewsWire • 08/01/22
Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseZacks Investment Research • 08/01/22
Apellis Pharmaceuticals, Inc. (APLS) Moves 16.3% Higher: Will This Strength Last?Zacks Investment Research • 07/20/22
Apellis Surges And Breaks Out As FDA Mulls Its Eye-Disease TreatmentInvestors Business Daily • 07/19/22
HC Wainwright Initiates Coverage On Upcoming Complement Franchise Company Apellis PharmaceuticalsBenzinga • 07/19/22
Apellis Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of Geographic Atrophy (GA)GlobeNewsWire • 07/19/22
Apellis Announces Five Oral Presentations in Geographic Atrophy (GA) Highlighted at the ASRS Annual Scientific MeetingGlobeNewsWire • 07/14/22
Apellis and Sobi Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI® (pegcetacoplan) for PNH at EHA 2022 CongressGlobeNewsWire • 06/10/22
Apellis (APLS), Sobi Begin Pegcetacoplan Dosing in Kidney DiseaseZacks Investment Research • 06/08/22
Apellis and Sobi Announce First Patient Dosed in Phase 3 VALIANT Study of Pegcetacoplan for IC-MPGN and C3G, Rare Kidney Diseases with High Unmet Medical NeedGlobeNewsWire • 06/07/22
Why Is Apellis Pharmaceuticals, Inc. (APLS) Down 4.5% Since Last Earnings Report?Zacks Investment Research • 06/03/22